Earlier this year at the World Orphan Drug Congress Asia we heard Gary Pasternack, CEO of Asklepion Pharmaceuticals deliver the presentation: Evaluating Market Access & Business Opportunities in Asia’s Orphan Drug Industry.
Some points covered in this presentation include:
- Forecasted Worldwide Orphan Drug Sales 2004-2018
- Cumulative Orphan Drug Designations
- Orphan Drug Designations
- Few Orphan Drugs Reach Asia-Pacific
- Five Trends Shaping Sales Performance Across the Globe
- 5 Barriers for Orphan Drugs in Asia Pacific
- Essential Medicines vs. Orphan Drugs
- Asia’s Opportunity
- Evaluating Market Access & Business Opportunities
- Asia’s Population
- Asia’s Ability to Pay?
- Orphan Drug Legal Framework
- Orphan Drug Financial Framework
- Orphan Drug Pricing & Reimbursement Framework
- Orphan Drug Public Awareness
- Asia’s Trading Partners
- Awareness of International Organizations
- Emerging Markets, Emerging Opportunities
- Partnership